Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1992;106(1):111-7.
doi: 10.1007/BF02253597.

5-HT1A receptor-effector system responsivity in panic disorder

Affiliations
Clinical Trial

5-HT1A receptor-effector system responsivity in panic disorder

K P Lesch et al. Psychopharmacology (Berl). 1992.

Abstract

To explore 5-HT1A receptor responsivity in panic disorder (PD), hypothermic, neuroendocrine and behavioral responses to the selective partial 5-HT1A receptor agonist ipsapirone (IPS) were investigated in patients with primary PD and healthy controls. Fourteen patients and matched controls received a single oral dose of 0.3 mg/kg IPS or placebo under double-blind, random-assignment conditions. IPS induced hypothermia and corticotropin (ACTH)/cortisol release but had only minimal effects on behavior. Compared with controls, the patients with PD exhibited significantly attenuated thermoregulatory and neuroendocrine responses to IPS. Although the healthy subjects reported increased drowsiness and the PD patients rated themselves more nervous and less calm following administration of IPS, no consistent changes in ratings of anxiety or panic symptoms were recorded. The impaired hypothermic and ACTH/cortisol responses following 5-HT1A receptor activation reflects subsensitivity of both the pre- and post-synaptic 5-HT1A receptor-effector system, thus supporting the hypothesis that a 5-HT1A receptor-related serotonergic dysfunction may be linked to the pathophysiology of PD. Future studies of 5-HT1A receptor-effector complex function in conjunction with assessment of the responsivity of other subtypes (e.g. 5-HT2, 5-HT3) should promote the evaluation of 5-HT system integrity in anxiety disorders and its involvement in anxiolytic drug effects.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Eur J Pharmacol. 1988 Mar 15;147(3):431-9 - PubMed
    1. Biol Psychiatry. 1989 Jun;26(2):203-5 - PubMed
    1. Psychiatry Res. 1988 Jul;25(1):101-4 - PubMed
    1. Br J Pharmacol. 1988 May;94(1):137-47 - PubMed
    1. Trends Pharmacol Sci. 1989 Feb;10(2):64-9 - PubMed

Publication types

LinkOut - more resources